Core Viewpoint - The price of experimental monkeys, particularly for the 3-5 year old crab-eating macaques, has surged to 140,000 yuan each, indicating a supply-demand imbalance in the market. This trend is expected to benefit companies like Zhaoyan New Drug, which possess valuable resources in this area [1] Company Summary - Zhaoyan New Drug's stock has seen an increase of over 4%, currently trading at 24 Hong Kong dollars with a transaction volume of 108 million Hong Kong dollars [1] - The company has access to high-quality and scarce experimental monkey resources, which contribute to a stable profit base through annual sales of a certain number of monkeys for internal use [1] - In the context of tightening supply of experimental monkeys, Zhaoyan New Drug may gain stronger bargaining power, potentially leading to increased order rates and the ability to charge premium service fees [1] Industry Summary - The supply of experimental monkeys is declining while demand is stabilizing and recovering, driven by new technologies such as small nucleic acids and CAR-T, which require the use of experimental monkeys [1] - The gap between supply and demand for experimental monkeys is widening, leading to an upward trend in monkey prices [1]

Group 1 - The core viewpoint of the article highlights the rising price of experimental monkeys, particularly for the species used in research, which has reached 140,000 yuan each, indicating a supply-demand imbalance in the market [1] - Changjiang Securities reports that the supply of experimental monkeys is decreasing while demand is stabilizing and increasing, particularly due to new technologies like small nucleic acids and CAR-T that require these monkeys, leading to a widening supply-demand gap [1] - The company, Zhaoyan New Drug, possesses valuable and scarce resources of experimental monkeys, which not only contributes to a stable profit base through annual sales but also enhances its bargaining power in a tightening supply environment, potentially leading to increased order rates and service fee premiums [1]

昭衍新药（603127）(06127)发布公告，于2026年1月7日，注销有关2021年和2022年A股员工持股计划的 12.91万股库存股份。 ...

智通财经APP讯，昭衍新药(06127)发布公告，于2026年1月7日，注销有关2021年和2022年A股员工持股 计划的12.91万股库存股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 北京昭衍新藥研究中心股份有限公司 呈交日期： 2026年1月7日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 603127 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔 ...

证券之星消息，1月7日医疗服务板块较上一交易日上涨1.7%，益诺思领涨。当日上证指数报收于 4085.77，上涨0.05%。深证成指报收于14030.56，上涨0.06%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688710 | 益诺思 | 55.31 | 20.00% | 5.97万 | | 3.17亿 | | 688222 | 成都先导 | 30.44 | 13.67% | 44.49万 | | 13.43亿 | | 301293 | 三博脑科 | 93.82 | 10.45% | 74.53万 | | 68.62亿 | | 002173 | 创新医疗 | 28.63 | 9.99% | 10.16万 | | 2.91亿 | | 688621 | 阳光诺和 | 72.10 | 7.77% | 6.88万 | | 4.95 乙 | | 603127 | 昭衍新药 | 41.30 | 7.41% | 36.68万 | | 14.97亿 | | ...

Summary of Key Points from the Conference Call Transcript Industry Overview - **Industry Focus**: China Healthcare, specifically Contract Development and Manufacturing Organizations (CDMOs) [2][80] Core Insights and Arguments - **Catalysts for CDMOs**: The first quarter of 2026 is expected to have multiple catalysts impacting valuations, including geopolitical factors, regulatory milestones, and management insights from broker conferences [2][5] - **Company-Specific Events**: - **WuXi AppTec Co Ltd (603259.SS)**: Potential non-inclusion in the US Pentagon's military list on January 30, 2026, is considered a high-importance event with a modest upside surprise [6] - **Genscript Biotech Corporation (1548.HK)**: Expected to turn profitable in Q1 2026, also facing potential non-inclusion in the US Pentagon's military list [6] - **WuXi Biologics Cayman Inc (2269.HK)**: Participation in a broker healthcare conference on January 12, 2026, is deemed very high importance [6] - **Joinn Laboratories China Co Ltd (6127.HK)**: Anticipating a persistent shortage of lab monkeys in Q1 2026, which is a high-importance event [6] Financial Metrics and Valuation Methodology - **Genscript Biotech Corporation**: Valuation based on P/E, P/S, and DCF methodologies with a WACC of 10% and a terminal growth rate of 2% [7] - **WuXi XDC Cayman Inc (2268.HK)**: Valuation derived from DCF methodology, assuming a WACC of 10% and a terminal growth rate of 5% [8] - **WuXi Biologics Cayman Inc (2269.HK)**: Valuation based on DCF with a WACC of 8.4% and a terminal growth rate of 4% [9] Risks Identified - **Upside Risks**: - Better-than-expected growth in the Cell and Gene Therapy (CGT) market and increased outsourcing of CGT R&D [11] - Rapid ramp-up of late-stage projects and successful launches of blockbuster products [12] - **Downside Risks**: - Potential slowdown in biotech funding and pipeline progression [12] - Regulatory pressures and competition leading to margin pressures [16] Additional Important Information - **Market Sentiment**: The overall view of the CDMO industry is attractive, with expectations of growth driven by various catalysts [2] - **Company Ratings**: Companies like WuXi AppTec and Genscript Biotech are highlighted for their potential upside based on upcoming events and market conditions [6][80] This summary encapsulates the key points from the conference call, focusing on the industry dynamics, company-specific events, financial metrics, and identified risks.

Group 1 - The CRO (Contract Research Organization) sector in the Hong Kong stock market has shown strong performance, with notable gains across various companies [1] - Specifically, Kailaiying has increased by over 7%, while Tigermed and Zhaoyan Pharmaceutical have risen by over 5% [1] - Other companies such as WuXi AppTec and Kanglong Chemical have seen increases of over 3%, and WuXi Biologics and Kingsoft have gained over 2% [1]

Group 1 - The A-share market saw a collective rise in innovative drug concept stocks on January 7, with notable gains including a 20% increase for Beibete-U and over 17% for Yinos. [1] - Other significant performers included Chengdu XianDao with a 13% rise, and Panlong Pharmaceutical reaching a 10% increase. [1] - Additional stocks such as Yangguang Nuohuo and Zhaoyan New Drug also experienced gains exceeding 9% and 7% respectively. [1] Group 2 - The table lists various stocks with their respective codes, showing percentage increases, total market capitalization, and year-to-date performance. [2] - Beibete-U (688759) had a market cap of 18.6 billion with a year-to-date increase of 42.46%. [2] - Yinos (688710) reported a market cap of 7.611 billion and a year-to-date increase of 22.29%. [2] - Chengdu XianDao (688222) had a market cap of 12.2 billion and a year-to-date increase of 29.59%. [2] - Other stocks listed include Panlong Pharmaceutical (002864) with a market cap of 3.706 billion and a year-to-date increase of 13.07%, and Yangguang Nuohuo (688621) with a market cap of 8.188 billion and a year-to-date increase of 17.63%. [2]

格隆汇1月7日｜A股市场创新药概念股集体上涨，其中，必贝特-U 20CM涨停，益诺思涨超17%，成都 先导涨超13%，盘龙药业10CM涨停，阳光诺和涨超9%，昭衍新药、前沿生物、迈威生物、益方生物涨 超7%，悦康药业涨超6%。 | 代码 | 名标 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 688759 | 1 必贝特-U | | 20.00 | 186亿 | 42.46 | | 688710 | 益裙思 | | 17.14 | 76.11亿 | 22.29 | | 688222 | 成都先导 | 1 | 13.48 | 122亿 | 29.59 | | 002864 | 盘龙药业 | | 10.00 | 37.06亿 | 13.07 | | 688621 | 阳光诺和 | | 9.28 | 81.88 Z | 17.63 | | 603127 | 昭衍新药 | 1 | 7.83 | 311亿 | 18.42 | | 688221 | 前沿生物-l * | | 7.72 | 2665.06 | 33.68 | | 68 ...